Nanotechnology-based strategies against SARS-CoV-2 variants

Xiangang Huang(Brigham and Women's Hospital), Edo Kon(Tel Aviv University), Xuexiang Han(University of Pennsylvania), Xingcai Zhang(Harvard University), Na Kong(Brigham and Women's Hospital), Michael J. Mitchell(California Institute for Regenerative Medicine), Dan Peer(Tel Aviv University), Wei Tao(Brigham and Women's Hospital)

Nature Nanotechnology

August 18, 2022

10.1038/s41565-022-01174-5

Cited by 139Open Access

Abstract

Related Papers

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel, Kay M Tomashek, Lori E. Dodd et al.|New England Journal of Medicine|2020|7.7k

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Jun Lan, Jiwan Ge, Jinfang Yu et al.|Nature|2020|6.7k

Nanobodies: Natural Single-Domain Antibodies

Serge Muyldermans|Annual Review of Biochemistry|2013|2.3k

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Vanessa Monteil, Hyesoo Kwon, Patricia Prado et al.|Cell|2020|2.3k

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Norbert Pardi, Michael J. Hogan, Martin S. Naradikian et al.|The Journal of Experimental Medicine|2018|518